Counter‐regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo‐controlled, double‐blind, crossover trial

Abstract

Liraglutide did not compromise hypoglycaemic responses in type 1 diabetes after 4 weeks' treatment.